Builder
Tanishq Mathew Abraham
Co-founder & CEO, Sophont
Built Holon-S1, a model predicting tumor gene activity from routine pathology slides; co-founded Sophont and MedARC.
Real Alpha has cut 5 moments of Tanishq Mathew Abraham (Co-founder & CEO, Sophont) talking, from an interview on MTS published Oct 21, 2026.
What Tanishq Mathew Abraham said
- 0:36
Tumor slides can reveal biology that guides personalized care
“this one gene, which was actually then targeted by the medical team for treatment for this patient”
at 4:13 - 9:32
Cancer AI could support research, drug development, and care
“if you can predict the treatment response using the features from Hall and S1, then you can tell a patient”
at 11:27 - 12:33
AI drug discovery needs evidence from human biology
“we need to actually be training AI models on clinical data and on human biology.”
at 13:47 - 21:20
Cancer AI tools could reach clinical trials within a year
“some of these tools could potentially reach these clinical trials, at the very least, definitely like retrospective trials, potentially even prospective trials.”
at 21:50 - 15:07
Patient tests may matter before new drugs reach the clinic
“that can be done in a lot quicker timeline, in my opinion, compared to like developing drugs from scratch.”
at 16:39
- 0:36
Is this you? Add the badge to your site.
